| Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. | |
| | |
MedLine Citation:
|
PMID: 9316509 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: The Probucol Angioplasty Restenosis Trial was a prospective, randomized, controlled study that investigated the effectiveness of probucol therapy in reducing the rate of restenosis after percutaneous transluminal coronary angioplasty (PTCA). BACKGROUND: Antioxidants have an inhibitory effect on smooth muscle cell growth in experiments in vitro and in vivo, which suggests a possible pharmacologic effect on restenosis after PTCA. METHODS: One hundred one patients were randomly assigned to receive 1,000 mg/day of probucol or control (no lipid-lowering) therapy 4 weeks before PTCA. After 4 weeks of premedication, both groups underwent PTCA. Probucol was continued until follow-up angiography 24 weeks after PTCA. Angiographic results were analyzed at a core laboratory by quantitative coronary angiography. RESULTS: Dilation was successful in 46 of 50 patients in the probucol group and 45 of 51 in the control group. At follow-up angiography 24 weeks after angioplasty, angiographic restenosis occurred in 9 (23%) of 40 patients in the probucol group and 22 (58%) of 38 in the control group (p = 0.001). Minimal lumen diameter was 1.49 +/- 0.75 mm (mean +/- SD) in the probucol group and 1.13 +/- 0.65 mm in the control group (p = 0.02). Percent diameter stenosis at follow-up angiography in the probucol group was significantly lower than that in the control group (43.9% vs. 56.4%, p = 0.009). The late loss was 0.37 +/- 0.69 mm in the probucol group and 0.60 +/- 0.62 mm in the control group (p = 0.13). The loss/gain ratio was 0.32 +/- 0.74 in the probucol group and 0.56 +/- 0.81 in the control group (p = 0.059). Net gain was greater in the probucol group than in the control group (0.77 +/- 0.70 vs. 0.48 +/- 0.59 mm, p = 0.053). CONCLUSIONS: Probucol administered beginning 4 weeks before PTCA appears to reduce restenosis rates. |
| | |
Authors:
|
H Yokoi; H Daida; Y Kuwabara; H Nishikawa; F Takatsu; H Tomihara; Y Nakata; Y Kutsumi; S Ohshima; S Nishiyama; A Seki; K Kato; S Nishimura; T Kanoh; H Yamaguchi |
Related Documents
:
|
21218759 - Sequelae of neonatal septic arthritis of hip. 23669129 - Medical outcomes associated with nonmedical use of methadone and buprenorphine. 19303579 - Risk factors for mortality in patients with mediastinitis after cardiac surgery. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 30 ISSN: 0735-1097 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 1997 Oct |
Date Detail:
|
Created Date: 1997-10-30 Completed Date: 1997-10-30 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 855-62 Citation Subset: AIM; IM |
Affiliation:
|
Department of Cardiology, Juntendo University, Tokyo, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Angioplasty, Transluminal, Percutaneous Coronary* Anticholesteremic Agents / therapeutic use* Antioxidants / therapeutic use* Cholesterol / blood Combined Modality Therapy Coronary Angiography Coronary Disease / blood, radiography, therapy* Female Humans Male Middle Aged Premedication* Probucol / therapeutic use* Prospective Studies Recurrence Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Antioxidants; 23288-49-5/Probucol; 57-88-5/Cholesterol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: First international new intravascular rigid-flex endovascular stent study (FINESS): clinical and ang...
Next Document: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Tri...